About Me

My Goal: Run the Boston Marathon on April 15, 2019 with the Dana-Farber Marathon Challenge. Raise $17,000 (or more!) where 100% of funds raised benefit the Claudia Adams Barr Program in Innovative Basic Cancer Research. I run in honor of my friend Chris Davie who is battling brain cancer. I also run in honor for my friend RJ and his continued cancer-free life, in memory of Heather Thomson, and for other family and friends who are or have battled cancer. Together we can help Dana-Farber Cancer Institute reach the ultimate finish line: a world without cancer

Barr Program Impact Statements

Barr Program Impact Statements

Immunotherapies: New Ways to Activate the Immune System—An important area of cancer research asks why the human body's defense systems do not always attack and destroy tumors as they form. Funded by the Claudia Adams Barr Program, Glenn Dranoff, MD, discovered complex regulatory pathways in the human immune system that cancers exploit in order to escape destruction. Reversal of these effects can lead to the development of vaccines against cancer, like Provenge for prostate cancer. This research has also enabled the development of immune-activating drugs such as ipilimumab, which showed striking effects in melanoma in a trial led by Dana-Farber scientists and is now approved by the Food and Drug Administration for treatment.

Monday, November 30, 2015

Off to a great start!

With Giving Tuesday tomorrow, it's great to see that we've already raised $1,700 towards our goal of $13,100 this year!!  With several donations for our fundraiser received, DFMC2016 is shaping up to be another successful year.  Thank you to the Grafton Hospitality Group, Coolidge Corner Theatre and Cambridge, 1 for supporting DFMC and donating prizes for our opportunity drawing!  Coolidge Corner Theatre is a 4 time supporter and Grafton and Cambridge, 1 have supported us the last 3 years.  Great to have the support of such generous local businesses.






Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)